Medical devices, healthcare technology and the business of care
PMA approval · P240013

Sphere-9 Catheter and Affera Ablation System

Medtronic, Inc. · Decision date Oct 24, 2024

FDA DECISIONP240013

What did the FDA approve?

FDA records P240013 as an original PMA application. The recorded decision is approval, dated Oct 24, 2024.

FDA approval order statement

approval for the Sphere-9 Catheter and Affera Ablation System. This device is indicated for use in cardiac electrophysiological mapping (stimulation and electrogram recording) and for treatment of drug refractory, recurrent, symptomatic persistent atrial fibrillation (episode duration less than 1 year) and radiofrequency ablation of cavotricuspid isthmus dependent atrial flutter when used with the Affera mapping system.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Oct 24, 2024

FDA source record

Regulatory record facts

Identifier
P240013
Regulatory pathway
Premarket approval application
Product code
QZI
Decision code
APPR
Decision date
Oct 24, 2024
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.

Product code
QZI
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240013 received

    Application receipt date recorded by FDA.

  2. P240013 · FDA decision

    APPR

  3. P240013/S031 · Related supplement

    Sphere-9 Catheter and Affera Ablation System

  4. P240013/S028 · Related supplement

    Sphere-9 Catheter and Affera Ablation System

  5. P240013/S032 · Related supplement

    Affera Sphere-9 Mapping and Ablation Catheter

Timeline entries are records held by MedtechLedger for P240013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240013

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA supplementOct 2, 2026FDA
Medtronic, Inc.PMA supplementOct 6, 2026FDA
Medtronic, Inc.PMA supplementOct 9, 2026FDA

Explore the linked device profile

Other records with product code QZI

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementNov 3, 2026FDA
Kardium, Inc.PMA supplementOct 27, 2026FDA
Kardium, Inc.PMA supplementOct 23, 2026FDA
Volt PFA SystemP250022/S002
ABBOTT MEDICALPMA supplementOct 15, 2026FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. N.E, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records